Epistasis Between HLA-DRB1*16:02:01 and SLC16A11 T-C-G-T-T Reduces Odds for Type 2 Diabetes in Southwest American Indians
Diabetes · 2024
DOI: 10.2337/db23-0925 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2024. Verfasst von Robert C Williams und 6 weiteren Autor:innen. Beteiligte Einrichtung: Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, P…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Epistasis, Genetic, Genetic Predisposition to Disease, HLA-DRB1 Chains. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural Research Program of the NIH, NIDDK.
Themen: Diabetes mellitus
Abstract (Originalsprache)
We sought to identify genetic/immunologic contributors of type 2 diabetes (T2D) in an indigenous American community by genotyping all study participants for both high-resolution HLA-DRB1 alleles and SLC16A11 to test their risk and/or protection for T2D. These genes were selected based on independent reports that HLA-DRB1*16:02:01 is protective for T2D and that SLC16A11 associates with T2D in individuals with BMI <35 kg/m2. Here, we test the interaction of the two loci with a more complete data set and perform a BMI sensitivity test. We defined the risk protection haplotype of SLC16A11, T-C-G-T-T, as allele 2 of a diallelic genetic model with three genotypes, SLC16A11*11, *12, and *22, where allele 1 is the wild type. Both earlier findings were confirmed. Together in the same logistic model with BMI ≥35 kg/m2, DRB1*16:02:01 remains protective (odds ratio [OR] 0.73), while SLC16A11 switches from risk to protection (OR 0.57 [*22] and 0.78 [*12]); an added interaction term was statistically significant (OR 0.49 [*12]). Bootstrapped (b = 10,000) statistical power of interaction, 0.4801, yielded a mean OR of 0.43. Sensitivity analysis demonstrated that the interaction is significant in the BMI range of 30–41 kg/m2. To investigate the epistasis, we used the primary function of the HLA-DRB1 molecule, peptide binding and presentation, to search the entire array of 15-mer peptides for both the wild-type and ancient human SLC16A11 molecules for a pattern of strong binding that was associated with risk and protection for T2D. Applying computer binding algorithms suggested that the core peptide at SLC16A11 D127G, FSAFASGLL, might be key for moderating risk for T2D with potential implications for type 1 diabetes. Article Highlights
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ.
- La Jolla Institute for Immunology, La Jolla, CA.
ORCID-Profile: Robert C Williams, Leslie J Baier
Förderung
- Intramural Research Program of the NIH, NIDDK
Zitieren
APA
Williams, R. C., Hanson, R. L., Peters, B., Kearns, K., Knowler, W. C., Bogardus, C., & Baier, L. J. (2024). Epistasis Between HLA-DRB1*16:02:01 and SLC16A11 T-C-G-T-T Reduces Odds for Type 2 Diabetes in Southwest American Indians. Diabetes. https://doi.org/10.2337/db23-0925
Vancouver
Williams RC, Hanson RL, Peters B, Kearns K, Knowler WC, Bogardus C, et al. Epistasis Between HLA-DRB1*16:02:01 and SLC16A11 T-C-G-T-T Reduces Odds for Type 2 Diabetes in Southwest American Indians. Diabetes. 2024. doi:10.2337/db23-0925
BibTeX
@article{Williams2024,
author = {Williams, Robert C and Hanson, Robert L and Peters, Bjoern and Kearns, Kendall and Knowler, William C and Bogardus, Clifton and Baier, Leslie J},
title = {Epistasis Between HLA-DRB1*16:02:01 and SLC16A11 T-C-G-T-T Reduces Odds for Type 2 Diabetes in Southwest American Indians},
journal = {Diabetes},
year = {2024},
doi = {10.2337/db23-0925}
}
EUVIMED